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Drug treatments constitute a substantial 
portion of all health-care interventions. 
Despite their notable benefits, however, 
drug treatments are beyond the reach of 
sizable population groups and in some 
parts of the world there is little access 
to safe and effective medications even 
though new drugs are constantly being 
developed. 
The effectiveness and safety of 
newly developed drugs are often viewed 
too optimistically.1,2 According to a Co-
chrane systematic review published re-
cently, new drugs are seldom found to be 
substantially better than existing treat-
ments.3 However, because of lack of full 
and transparent access to the protocols 
of many clinical trials, compounded by 
publication bias and selective reporting 
of their findings, the true effectiveness 
of many drugs remains unknown. It is 
a fact that the results of trials are more 
likely to be published if the findings 
are favourable than if they are not.4 In 
addition, some measured outcomes are 
never reported,5 which generally results 
in an overestimation of effectiveness and 
an underestimation of harmful effects. 
Thus, researchers and the public only 
come to know about those findings 
that are published and disclosed, and 
physicians prescribe treatments on the 
basis of this biased information. For all 
of these reasons, it is critically important 
that prescribing physicians have a source 
of information about drug effectiveness 
that is independent and as objective as 
possible. 
Truly independent drug bulletins 
– those produced without financial or 
editorial intervention from the phar-
maceutical industry, regulatory agencies 
and governments – are such a source.6 
They make a contribution to society by 
objectively comparing the effectiveness 
of different drugs. Independent drug 
bulletins began to appear in the 1960s, 
after the thalidomide scandal. At the 
time the pharmaceutical industry was 
producing new drugs that were modify-
ing health-care practices. In the 1970s, 
a group of physicians and pharmacists 
in France began to meet to discuss 
and prepare independent information 
about drugs for other physicians and 
pharmacists. The group, which came to 
be known as “Prescrire”, gained official 
recognition in 1980, when the French 
Minister of Health commissioned it to 
provide independent information to the 
drug authorities. The group was initially 
supported through government fund-
ing, but this was eventually suspended 
and its drug bulletin, Prescrire, has been 
fully independent since 1993.7 Prescire 
is an example of a truly independent 
drug bulletin. It publishes no advertise-
ments and is financed solely through 
subscriptions and training courses for 
health-care professionals. Its readership, 
mainly physicians and pharmacists liv-
ing in France, grew gradually until 2000, 
plateaued for several years, and jumped 
to about 35 000 in 2012 after the Euro-
pean Medicines Agency recommended 
the withdrawal of benfluorex.8 Prescrire 
is published in French, although some 
reports are available in English.
Prescrire’s articles and reports 
are the result of close collaboration 
among physicians and pharmacists. 
They are prepared by about 100 paid 
collaborators trained in the use of 
evidence-based approaches and have 
no individual authors. This 80-page, 
entertaining monthly bulletin contains 
reports, news and practical guidance. 
Each report is written by a main author 
and a co-author, who together conduct 
an exhaustive, systematic search of the 
information available on a given drug 
(i.e. published articles, reviews and 
guidelines, agency reports, reports ob-
tained from pharmaceutical companies) 
and prepare a critical appraisal. After the 
co-authors and the editor in charge have 
reached agreement on a final draft, every 
report is reviewed by 15 to 40 internal 
and external peers before being revised 
and finalized by the authors and the bul-
letin’s editorial committee. Additional 
reports, including the annual financial 
statement, are available on the bulletin’s 
web site. Prescrire is influential in official 
drug-related decisions and daily drug 
use in France.
There is a definite place for indepen-
dent drug bulletins.6 The International 
Society of Drug Bulletins lists 50 of these 
publications, mainly from Europe and 
South America.9 Regardless of the diffi-
culty of relying solely on subscriptions to 
pay for the collaborators’ hard work, the 
model merits being widely reproduced. 
Yet despite their vital role, independent 
drug bulletins cannot begin to compen-
sate for the lack of transparency in the 
reporting of clinical research.10 Of all 
the clinical trials that are conducted, 
only about half publish their results 
and those that yield positive findings 
are selectively published more often.11 
This is inadmissible. Everything from 
the key components of the protocol to 
the full data set must be made available 
for public scrutiny. To achieve this goal, 
authorities as well as national and inter-
national agencies must be persuaded, 
through strong and persistent advocacy, 
to adopt and enforce measures mandat-
ing the transparency of the entire clinical 
research process.  ■
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